Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients.

Kovesdy CP, Rowan CG, Conrad A, Spiegel DM, Fogli J, Oestreicher N, Connaire JJ, Winkelmayer WC.

Kidney Int Rep. 2018 Oct 29;4(2):301-309. doi: 10.1016/j.ekir.2018.10.020. eCollection 2019 Feb.

2.

Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.

Bushinsky DA, Spiegel DM, Yuan J, Warren S, Fogli J, Pergola PE.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):103-110. doi: 10.2215/CJN.04500418. Epub 2018 Oct 31.

PMID:
30381412
3.

Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.

Pergola PE, Spiegel DM, Warren S, Yuan J, Weir MR.

Am J Nephrol. 2017;46(4):323-332. doi: 10.1159/000481270. Epub 2017 Oct 11.

4.

Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients.

Brunelli SM, Spiegel DM, Du Mond C, Oestreicher N, Winkelmayer WC, Kovesdy CP.

Nephrol Dial Transplant. 2018 Jul 1;33(7):1207-1214. doi: 10.1093/ndt/gfx241.

5.

Calcium Balance in Chronic Kidney Disease.

Hill Gallant KM, Spiegel DM.

Curr Osteoporos Rep. 2017 Jun;15(3):214-221. doi: 10.1007/s11914-017-0368-x. Review.

6.

Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval.

Brunelli SM, Du Mond C, Oestreicher N, Rakov V, Spiegel DM.

Am J Kidney Dis. 2017 Jul;70(1):21-29. doi: 10.1053/j.ajkd.2016.10.024. Epub 2017 Jan 19.

7.

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM.

JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.

8.

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis.

Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Block GA, Wilcox CS, Agarwal R.

Am J Nephrol. 2016;44(5):404-410. Epub 2016 Oct 27.

9.

Effect of Patiromer on Urinary Ion Excretion in Healthy Adults.

Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1769-1776. doi: 10.2215/CJN.01170216. Epub 2016 Sep 27.

10.

Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor.

Bushinsky DA, Block GA, Martin KJ, Bell G, Huang S, Sun Y, Spiegel DM, Walsh L, Mix TC, Kewalramani R.

Am J Nephrol. 2015;42(5):379-88. doi: 10.1159/000442754. Epub 2015 Dec 19.

PMID:
26684933
11.

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.

Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, D'Haese PC.

Kidney Int. 2015 Apr;87(4):846-56. doi: 10.1038/ki.2014.349. Epub 2014 Oct 22.

12.

Outpatient red blood cell transfusion payments among patients on chronic dialysis.

Gitlin M, Lee JA, Spiegel DM, Carson JL, Song X, Custer BS, Cao Z, Cappell KA, Varker HV, Wan S, Ashfaq A.

BMC Nephrol. 2012 Nov 2;13:145. doi: 10.1186/1471-2369-13-145.

13.

A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).

Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW, Silver S, Murday AS, Armitage JO, Goldsmith D.

Semin Thromb Hemost. 2012 Nov;38(8):783-96. doi: 10.1055/s-0032-1328884. Epub 2012 Oct 30. Review.

14.

Effects of phosphate binders in moderate CKD.

Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM.

J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19.

15.

Avoiding harm and achieving optimal dialysis outcomes--the dialysate component.

Spiegel DM.

Adv Chronic Kidney Dis. 2012 May;19(3):166-70. doi: 10.1053/j.ackd.2012.03.004.

PMID:
22578676
16.

A computerized treatment algorithm trial to optimize mineral metabolism in ESRD.

Spiegel DM, McPhatter L, Allison A, Drumheller JC, Lockridge R.

Clin J Am Soc Nephrol. 2012 Apr;7(4):632-9. doi: 10.2215/CJN.08170811. Epub 2012 Feb 2.

17.

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets.

Spiegel DM, Brady K.

Kidney Int. 2012 Jun;81(11):1116-22. doi: 10.1038/ki.2011.490. Epub 2012 Feb 1.

18.

Magnesium in chronic kidney disease: unanswered questions.

Spiegel DM.

Blood Purif. 2011;31(1-3):172-6. doi: 10.1159/000321837. Epub 2011 Jan 10. Review.

19.

Recombinant human erythropoietin dosing errors due to concentrated EPO.

Spiegel DM, Nemenoff RA.

Clin Nephrol. 2010 Jun;73(6):446-8.

PMID:
20497757
20.

A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3.

Tumlin J, Goldman J, Spiegel DM, Roer D, Ntoso KA, Blaney M, Jacobs J, Gillespie BS, Begelman SM.

Clin J Am Soc Nephrol. 2010 Apr;5(4):631-6. doi: 10.2215/CJN.06520909. Epub 2010 Feb 4.

21.

Ten-year experience with sevelamer and calcium salts as phosphate binders.

Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM.

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S31-40. doi: 10.2215/CJN.05880809. Review.

22.

Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.

Spiegel DM, Khan I, Krishnan M, Mayne TJ.

Am J Kidney Dis. 2010 Jan;55(1):113-20. doi: 10.1053/j.ajkd.2009.09.024. Epub 2009 Nov 22.

PMID:
19932539
23.

Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study.

Spiegel DM, Farmer B.

Hemodial Int. 2009 Oct;13(4):453-9. doi: 10.1111/j.1542-4758.2009.00364.x. Epub 2009 May 12.

PMID:
19469885
24.

How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis?

Bellasi A, Kooienga L, Block GA, Veledar E, Spiegel DM, Raggi P.

J Nephrol. 2009 Mar-Apr;22(2):255-62.

PMID:
19384844
25.

Lost without directions: lessons from the anemia debate and the drive study.

Spiegel DM, Chertow GM.

Clin J Am Soc Nephrol. 2009 May;4(5):1009-10. doi: 10.2215/CJN.00270109. Epub 2009 Apr 8. Review.

26.

Hemoglobin variability in chronic kidney disease: a cross-sectional study.

Spiegel DM.

Am J Med Sci. 2009 May;337(5):340-3. doi: 10.1097/MAJ.0b013e31818e5c08.

PMID:
19295412
27.

Interpreting observational studies of disordered mineral metabolism and mortality in patients on hemodialysis.

Spiegel DM.

Nat Clin Pract Nephrol. 2009 Jan;5(1):16-7. doi: 10.1038/ncpneph0992. Epub 2008 Nov 11.

PMID:
19002135
28.

Psychometric evaluation of the National Kidney Dialysis and Kidney Transplantation Study symptom checklist: reliability and validity.

Spiegel DM, Evans RW, Gitlin M, Mayne TJ.

Nephrol Dial Transplant. 2009 Feb;24(2):619-25. doi: 10.1093/ndt/gfn523. Epub 2008 Sep 17.

PMID:
18799605
29.

Factors affecting anemia management in hemodialysis patients: a single-center experience.

Spiegel DM, Gitlin M, Mayne T.

Hemodial Int. 2008 Jul;12(3):336-41. doi: 10.1111/j.1542-4758.2008.00278.x.

PMID:
18638090
30.

Should we be using calcium-containing phosphate binders in patients on dialysis?

Spiegel DM, Block GA.

Nat Clin Pract Nephrol. 2008 Mar;4(3):118-9. doi: 10.1038/ncpneph0710. Epub 2008 Jan 15. No abstract available.

PMID:
18212784
31.

Computer templates in chronic kidney disease care: a tool for improving patient management.

Rosenthal BJ, Spiegel DM.

Adv Chronic Kidney Dis. 2008 Jan;15(1):37-41.

PMID:
18155108
32.

Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.

Spiegel DM, Farmer B, Smits G, Chonchol M.

J Ren Nutr. 2007 Nov;17(6):416-22.

PMID:
17971314
33.

The role of magnesium binders in chronic kidney disease.

Spiegel DM.

Semin Dial. 2007 Jul-Aug;20(4):333-6. Review.

PMID:
17635824
34.

Factors associated with mortality in patients new to haemodialysis.

Spiegel DM, Raggi P, Smits G, Block GA.

Nephrol Dial Transplant. 2007 Dec;22(12):3568-72. Epub 2007 Jul 7.

PMID:
17617651
35.

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.

Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM.

Kidney Int. 2007 Mar;71(5):438-41. Epub 2007 Jan 3.

36.

Achieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practice.

Spiegel DM, Casey L, Bell S, Parker M, Chonchol M.

Hemodial Int. 2006 Oct;10 Suppl 2:S24-7.

PMID:
17022747
37.

Anemia management in chronic kidney disease: what have we learned after 17 years?

Spiegel DM.

Semin Dial. 2006 Jul-Aug;19(4):269-72. Review.

PMID:
16893402
38.

Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders.

Galassi A, Spiegel DM, Bellasi A, Block GA, Raggi P.

Nephrol Dial Transplant. 2006 Nov;21(11):3215-22. Epub 2006 Jul 28.

PMID:
16877490
39.

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.

Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P.

Kidney Int. 2005 Oct;68(4):1815-24.

40.

Coronary and aortic calcifications in patients new to dialysis.

Spiegel DM, Raggi P, Mehta R, Lindberg JS, Chonchol M, Ehrlich J, James G, Chertow GM, Block GA.

Hemodial Int. 2004 Jul 1;8(3):265-72. doi: 10.1111/j.1492-7535.2004.01104.x.

PMID:
19379426
41.

Comparison of cuffed tunneled hemodialysis catheter survival.

Rocklin MA, Dwight CA, Callen LJ, Bispham BZ, Spiegel DM.

Am J Kidney Dis. 2001 Mar;37(3):557-63.

PMID:
11228180
42.

Bioimpedance resistance ratios for the evaluation of dry weight in hemodialysis.

Spiegel DM, Bashir K, Fisch B.

Clin Nephrol. 2000 Feb;53(2):108-14.

PMID:
10711412
43.

Is low-molecular-weight heparin useful for venovenous hemofiltration in the intensive care unit?

Spiegel DM, Anderson RJ.

Crit Care Med. 1999 Oct;27(10):2316-7. Review. No abstract available.

PMID:
10548241
44.

The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.

Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA.

Chest. 1999 Oct;116(4):984-90.

PMID:
10531163
45.

The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.

Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA.

Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1580-4.

PMID:
10228130
46.
47.

Hemodialysis urea rebound: the effect of increasing dialysis efficiency.

Spiegel DM, Baker PL, Babcock S, Contiguglia R, Klein M.

Am J Kidney Dis. 1995 Jan;25(1):26-9.

PMID:
7810527
48.

Bioimpedance analysis of total body water in hemodialysis patients.

Ho LT, Kushner RF, Schoeller DA, Gudivaka R, Spiegel DM.

Kidney Int. 1994 Nov;46(5):1438-42. No abstract available.

49.

Serum albumin: a predictor of long-term outcome in peritoneal dialysis patients.

Spiegel DM, Breyer JA.

Am J Kidney Dis. 1994 Feb;23(2):283-5.

PMID:
8311088
50.

Serum albumin: a marker for morbidity in peritoneal dialysis patients.

Spiegel DM, Anderson M, Campbell U, Hall K, Kelly G, McClure E, Breyer JA.

Am J Kidney Dis. 1993 Jan;21(1):26-30.

PMID:
8418622

Supplemental Content

Loading ...
Support Center